3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
283
Specimen Handling
278
pembrolizumab
255
Cyclophosphamide
234
Radiotherapy
229
Nivolumab
183
Cisplatin
174
Biopsy
165
Carboplatin
155
Radiosurgery
142
fludarabine
130
Blood Specimen Collection
130
Gemcitabine
120
Surveys and Questionnaires
117
Paclitaxel
115
venetoclax
112
Standard of Care
112
Dexamethasone
105
Bevacizumab
96
Radiation
95
Rituximab
91
Oxaliplatin
89
Cytarabine
88
Capecitabine
86
Drug Therapy
85
Ipilimumab
83
Doxorubicin
81
durvalumab
80
fludarabine phosphate
73
Fluorouracil
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled